<DOC>
	<DOCNO>NCT00092508</DOCNO>
	<brief_summary>This dose comparison study , take place 200 site worldwide , compare dosing , safety efficacy investigational medicine OPC-6535 dosing , safety efficacy Asacol ® maintenance remission subject ulcerative colitis .</brief_summary>
	<brief_title>CORE : A Study OPC-6535 With Asacol® Maintaining Ulcerative Colitis ( UC ) Remission</brief_title>
	<detailed_description>Objective ( ) : This study compare safety efficacy 25 mg per day ( QD ) 50 mg QD OPC-6535 800 mg twice day ( BID ) Asacol® maintenance remission subject ulcerative colitis . Subject Population : - Subjects ulcerative colitis currently remission define rectal bleeding ( RB ) flexible sigmoidoscopy ( FS ) score 0 , stable dose sulfasalazine 5-ASA product least 6 week . - Subjects must diagnosis ulcerative colitis establish prior colonoscopy undergo colonoscopy lieu flexible sigmoidoscopy Screening Period . - Subjects must treatment flare ulcerative colitis , symptomatic onset remission occur 52 week Screening Period . - Subjects may use corticosteroid , topical agent ( corticosteroid 5-ASA enema , suppository , foam ) , azathioprine , 6-mercaptopurine , methotrexate within 6 week Screening Period . Upon entry , sulfasalazine 5-ASA containing product discontinue . Safety : Vital sign , ECGs , laboratory study ( include hematology , clinical chemistry , urinalysis ) , adverse event .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Mesalamine</mesh_term>
	<criteria>Male female subject , 18 80 year age , inclusive . Subjects prior diagnosis ulcerative colitis , establish colonoscopy . Subjects currently remission . Subjects undergone treatment flare ulcerative colitis , symptomatic onset remission occur 52 week Screening Period . If subject take sulfasalazine 5ASA product prior entry , dose must stable least 6 week prior Screening Period . NOTE : During study , use drug discontinue . Subjects undergone colonoscopy pancolonic surveillance biopsy negative dysplasia within 1 year Screening Visit increase risk colorectal cancer ( ≥ 8 year history ulcerative colitis ) . Female male subject surgically sterilize prepared agree practice doublebarrier form birth control Screening Period 30 day ( female ) 90 day ( male ) , respectively , last dose study medication . Females 12 month postmenopausal also eligible participate study . Subjects active disease . Subjects clinically significant disease ( ) condition/procedure ( ) . Subjects major gastrointestinal surgery include , limited , colostomy , ileostomy previous colonic surgery appendectomy . Subjects use corticosteroid topical agent ( corticosteroid 5ASA enema , suppository , foam ) within 6 week Screening Period . Female subject pregnant lactating . Other exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>Ulcerative Colitis Remission</keyword>
	<keyword>ulcerative</keyword>
	<keyword>colitis</keyword>
	<keyword>remission</keyword>
	<keyword>relapse</keyword>
	<keyword>Asacol®</keyword>
	<keyword>maintain</keyword>
	<keyword>maintenance</keyword>
	<keyword>flare</keyword>
	<keyword>rectal</keyword>
	<keyword>bleeding</keyword>
	<keyword>bowel</keyword>
</DOC>